<DOC>
	<DOC>NCT01024777</DOC>
	<brief_summary>The purpose of this study is to determine the safety and the immunologic effects of supplementation with low-dose and high-dose cholecalciferol (vitamin D3) in patients with multiple sclerosis.</brief_summary>
	<brief_title>Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Between ages of 1855 years (inclusive) Serum 25(OH) vitamin D levels between 2050 ng/mL and a candidate for vitamin D supplementation Patients with or without immunomodulatory therapy for RRMS Diagnosis of multiple sclerosis Serum 25(OH) vitamin D deficient level &lt; 20 ng/mL High dose vitamin D supplementation in the past 3 months Pregnancy History of tuberculosis, hyperparathyroidism, sarcoidosis or kidney stones Baseline serum creatinine above 1.5 Hypersensitivity to vitamin D preparations Milk allergy Unable to consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>cholecalciferol</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>vitamin D</keyword>
	<keyword>D3</keyword>
</DOC>